TP53 mutation influences the efficacy of treatment of colorectal cancer cell lines with a combination of sirtuin inhibitors and chemotherapeutic agents.

Yang, Hao; Chen, Ya; Jiang, Yuan; Wang, Dongliang; Yan, Jun; Zhou, Zhaoli

Yang, Hao; Chen, Ya; Jiang, Yuan; Wang, Dongliang; Yan, Jun; Zhou, Zhaoli.

Affiliation

Yang H; Department of Oncology, Jiading District Central Hospital Affiliated to Shanghai University of Medicine and Health Sciences, Shanghai 201800, P.R. China.
Chen Y; Shanghai Key Laboratory of Molecular Imaging, Shanghai University of Medicine and Health Sciences, Shanghai 201318, P.R. China.
Jiang Y; Shanghai Key Laboratory of Molecular Imaging, Shanghai University of Medicine and Health Sciences, Shanghai 201318, P.R. China.
Wang D; Shanghai Key Laboratory of Molecular Imaging, Shanghai University of Medicine and Health Sciences, Shanghai 201318, P.R. China.
Yan J; Shanghai Key Laboratory of Molecular Imaging, Shanghai University of Medicine and Health Sciences, Shanghai 201318, P.R. China.
Zhou Z; Department of Oncology, Jiading District Central Hospital Affiliated to Shanghai University of Medicine and Health Sciences, Shanghai 201800, P.R. China.

Exp Ther Med ; 20(2): 1415-1422, 2020 Aug.

Article in En | MEDLINE | ID: mdl-32742376